These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 34727333

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome.
    Mousavi T, Nikfar S, Abdollahi M.
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):583-604. PubMed ID: 32380874
    [Abstract] [Full Text] [Related]

  • 23. Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation.
    Liu JJ, Brenner DM.
    Gastroenterol Clin North Am; 2021 Sep; 50(3):639-653. PubMed ID: 34304792
    [Abstract] [Full Text] [Related]

  • 24. New treatment options for irritable bowel syndrome with predominant diarrhea.
    Weber HC.
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
    [Abstract] [Full Text] [Related]

  • 25. Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome.
    Biniszewska O, Jacenik D, Tarasiuk A, Fichna J.
    Expert Opin Pharmacother; 2024 Jun; 25(8):1039-1049. PubMed ID: 38856704
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
    Miner PB.
    Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
    [Abstract] [Full Text] [Related]

  • 28. Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey.
    Rangan V, Ballou S, Shin A, Camilleri M, Beth Israel Deaconess Medical Center GI Motility Working GroupDivision of Gastroenterology, Department of Internal Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts., Lembo A.
    Gastroenterology; 2020 Feb; 158(3):786-788.e1. PubMed ID: 31711922
    [Abstract] [Full Text] [Related]

  • 29. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
    Rothstein RD, Friedenberg FK.
    Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
    [Abstract] [Full Text] [Related]

  • 30. New pharmacological treatment options for irritable bowel syndrome with constipation.
    Nusrat S, Miner PB.
    Expert Opin Emerg Drugs; 2015 Oct; 20(4):625-36. PubMed ID: 26548544
    [Abstract] [Full Text] [Related]

  • 31. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
    Fock KM, Wagner A, Asia Pacific Gastroenterology Group.
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
    [Abstract] [Full Text] [Related]

  • 32. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
    Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.
    Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
    [Abstract] [Full Text] [Related]

  • 33. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
    Lacy BE.
    Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
    [Abstract] [Full Text] [Related]

  • 34. Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis.
    Shah ED, Chang L, Salwen-Deremer JK, Gibson PR, Keefer L, Muir JG, Eswaran S, Chey WD.
    Am J Gastroenterol; 2021 Apr; 116(4):748-757. PubMed ID: 33982945
    [Abstract] [Full Text] [Related]

  • 35. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
    Jadallah KA, Kullab SM, Sanders DS.
    World J Gastroenterol; 2014 Jul 21; 20(27):8898-909. PubMed ID: 25083062
    [Abstract] [Full Text] [Related]

  • 36. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.
    Lacy BE.
    Aliment Pharmacol Ther; 2018 Oct 21; 48(8):817-830. PubMed ID: 30194692
    [Abstract] [Full Text] [Related]

  • 37. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
    Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG.
    Clin Gastroenterol Hepatol; 2004 Aug 21; 2(8):675-82. PubMed ID: 15290660
    [Abstract] [Full Text] [Related]

  • 38. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM, Shiff SJ, Quigley EM.
    Curr Med Res Opin; 2013 Feb 21; 29(2):149-60. PubMed ID: 23198977
    [Abstract] [Full Text] [Related]

  • 39. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
    Scarpellini E, Laterza L, Ianiro G, Tack J, Abenavoli L, Gasbarrini A.
    Expert Opin Pharmacother; 2016 Jul 21; 17(10):1395-402. PubMed ID: 27267380
    [Abstract] [Full Text] [Related]

  • 40. Rifaximin for the treatment of irritable bowel syndrome.
    Cremonini F, Lembo A.
    Expert Opin Pharmacother; 2012 Feb 21; 13(3):433-40. PubMed ID: 22251066
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.